NovoCure Limited
As of Oct 22, 2026, NovoCure is in Stage 3, the topping phase, now in week 3 (since Oct 2, 2026). It closed at $15.10, 24.5% below its 52-week high and above its 200-day average, which is rising.
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United… More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is NVCR early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
NVCR among Medical Devices42nd of 141 by relative strength
All 141 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | TXG | Stage 2 · wk 48 | 99 | −7.8% |
| 2 | RCEL | Stage 2 · wk 13 | 98 | +40.8% |
| 3 | BFLY | Stage 2 · wk 26 | 98 | −26.0% |
| 4 | HAE | Stage 2 · wk 17 | 96 | +8.7% |
| 5 | GKOS | Stage 2 · wk 25 | 96 | +15.1% |
| 6 | AXGN | Stage 3 · wk 2 | 95 | −15.3% |
| 7 | NEOG | Stage 2 · wk 14 | 95 | −11.7% |
| 8 | BVS | Stage 2 · wk 15 | 95 | +10.5% |
| …42 | NVCR | Stage 3 · wk 3 | 60 | −7.1% |
NovoCure: quick answers
What stage is NovoCure in?
As of Oct 22, 2026, NovoCure (NVCR) is in Stage 3, the topping phase. It entered Stage 3 on Oct 2, 2026 and is in week 3. What the four stages mean
Is NovoCure in an uptrend?
Its uptrend has stalled. NovoCure is in Stage 3, the topping phase that follows an advance. It trades 1.9% above its 200-day average, which is rising.
How far is NovoCure from its 52-week high?
NovoCure closed at $15.10 on Oct 22, 2026, 24.5% below its 52-week high of $19.99. Its 52-week low is $10.03.
How has NovoCure performed over the past year?
As of Oct 22, 2026, NovoCure is up 6.9% over the past year and up 15.1% so far in 2026.
Which sector and industry is NovoCure in?
NovoCure is in the Medical Devices industry, part of the Health Care sector.
About this companyHealth Care· Medical Devices
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.